Decompensated heart failure and cachexia: Is it time to legalize anabolics?

International Journal of Cardiology

Volumn 111, Issue 1, 2006, Pages 185-186

  Filippatos, Gerasimos ^a   Rauchhaus, Mathias ^b   Anker, Stefan D ^b,c  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; HUMAN GROWTH HORMONE;

APOPTOSIS; ARTICLE; BONE MASS; CACHEXIA; CLINICAL TRIAL; HEALTH CARE COST; HEART FAILURE; HEMODYNAMICS; HOSPITALIZATION; HUMAN; MORBIDITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 33746286969     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.06.002     Document Type: Note

References (20)

1. Gheorghiade M., Zannad F., Sopko G., et al. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 112 25 (2005 (Dec 20)) 3958-3968
2. Anker S.D., Ponikowski P., Varney S., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
3. Filippatos G.S., Tsilias K., Venetsanou K., et al. Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system. Int J Cardiol 76 (2000) 117-122
4. Filippatos G. Cardiac cachexia. Is it time to legalize anabolics?. Hellen J Cardiol 45 (2004) 282-287
5. Rosenthal N., and Musaro A. Gene therapy for cardiac cachexia?. Int J Cardiol 85 1 (2002 (Sep)) 185-191
6. Coats A.J. Advances in the non-drug, non-surgical, non-device management of chronic heart failure. Int J Cardiol 100 1 (2005 (Apr 8)) 1-4
7. Akashi Y.J., Springer J., and Anker S.D. Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. Curr Heart Fail Rep 2 4 (2005 (Dec)) 198-203
8. Anker S.D., Steinborn W., and Strassburg S. Cardiac cachexia. Ann Med 36 (2004) 518-529
9. Sharma R., and Anker S.D. Cytokines apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 85 (2002) 161-171
10. Filippatos G.S., Kanatselos C., Manolatos D.D., et al. Studies on apoptosis and fibrosis in skeletal musculature: a comparison of heart failure patients with and without cardiac cachexia. Int J Cardiol 90 1 (2003 (Jul)) 107-113
11. Filippatos G.S., Anker S.D., and Kremastinos D.T. Pathophysiology of peripheral muscle wasting in cardiac cachexia. Curr Opin Clin Nutr Metab Care 8 3 (2005 (May)) 249-254
12. Filippatos G.S., Anker S.D., and Kardaras F. B-type natriuretic peptide serum levels in acute heart failure. Eur Heart J 25 12 (2004 (Jun)) 1085-1086
13. Lainscak M., Keber I., and Anker S.D. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol 106 3 (2006 (Jan 26)) 319-322
14. Anker S.D., Negassa A., Coats A.J., et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 361 (2003) 1077-1083
15. Mulligan K., and Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol 85 1 (2002 (Sep)) 151-159
16. Bocchi E., Moura L., Guimaraes G., Conceicao Souza G.E., and Ramires J.A. Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure. Int J Cardiol 110 3 (2006) 313-317
17. Genth-Zotz S., Zotz R., Geil S., Voigtlander T., Meyer J., and Darius H. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation 99 (1999) 18-21
18. Strassburg S., Springer J., and Anker S.D. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 37 10 (2005 (Oct)) 1938-1947
19. Khardori R., Taraben A., Taylor G.J., and Falcone M. Growth hormone in end-stage heart failure. Lancet 349 (1997) 1841-1842
20. Frustaci A., Chimenti C., Setoguchi M., et al. Cell death in acromegalic cardiomyopathy. Circulation 99 (1999) 1426-1434